143 related articles for article (PubMed ID: 31246479)
1. Low-Frequency Raman Spectroscopic Study on Compression-Induced Destabilization in Melt-Quenched Amorphous Celecoxib.
Be Rziņš KR; Fraser-Miller SJ; Rades T; Gordon KC
Mol Pharm; 2019 Aug; 16(8):3678-3686. PubMed ID: 31246479
[TBL] [Abstract][Full Text] [Related]
2. Combined Effect of the Preparation Method and Compression on the Physical Stability and Dissolution Behavior of Melt-Quenched Amorphous Celecoxib.
Be Rziņš KR; Fraser-Miller SJ; Di R; Liu J; Peltonen L; Strachan CJ; Rades T; Gordon KC
Mol Pharm; 2021 Mar; 18(3):1408-1418. PubMed ID: 33586988
[TBL] [Abstract][Full Text] [Related]
3. Investigation on Formulation Strategies to Mitigate Compression-Induced Destabilization in Supersaturated Celecoxib Amorphous Solid Dispersions.
Be Rziņš KR; Fraser-Miller SJ; Walker GF; Rades T; Gordon KC
Mol Pharm; 2021 Oct; 18(10):3882-3893. PubMed ID: 34529437
[TBL] [Abstract][Full Text] [Related]
4. Low-Frequency Raman Spectroscopy as an Avenue to Determine the Transition Temperature of β- and γ-Relaxation in Pharmaceutical Glasses.
Be Rziņš KR; Fraser-Miller SJ; Rades T; Gordon KC
Anal Chem; 2022 Jun; 94(23):8241-8248. PubMed ID: 35647784
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
6. Microscopic Cracks Modulate Nucleation and Solid-State Crystallization Tendency of Amorphous Celecoxib.
Thakore SD; Das K; Dalvi SV; Reddy CM; Bansal AK
Mol Pharm; 2024 Jan; 21(1):76-86. PubMed ID: 38051598
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
[TBL] [Abstract][Full Text] [Related]
8. Preparation of celecoxib tablet by hot melt extrusion technology and application of process analysis technology to discriminate solubilization effect.
Hwang I; Renuka V; Lee JH; Weon KY; Kang CY; Lee BJ; Park JB
Pharm Dev Technol; 2020 Jun; 25(5):525-534. PubMed ID: 31985320
[TBL] [Abstract][Full Text] [Related]
9. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
Aucamp M; Milne M; Liebenberg W
AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
[TBL] [Abstract][Full Text] [Related]
10. The Development of Quasi-isothermal Calorimetry for the Measurement of Drug-Polymer Miscibility and Crystallization Kinetics: Olanzapine-Loaded PLGA Microparticles.
Askin S; Zhao M; Gonçalves AD; Gaisford S; Craig DQM
Mol Pharm; 2018 Aug; 15(8):3332-3342. PubMed ID: 29933697
[TBL] [Abstract][Full Text] [Related]
11. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
Xie T; Taylor LS
Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
[TBL] [Abstract][Full Text] [Related]
12. Comparison of amorphous states prepared by melt-quenching and cryomilling polymorphs of carbamazepine.
Guinet Y; Paccou L; Danède F; Willart JF; Derollez P; Hédoux A
Int J Pharm; 2016 Jul; 509(1-2):305-313. PubMed ID: 27237427
[TBL] [Abstract][Full Text] [Related]
13. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of generation of drug nanocrystals in celecoxib: mannitol nanocrystalline solid dispersion.
Bhatt V; Shete G; Bansal AK
Int J Pharm; 2015 Nov; 495(1):132-139. PubMed ID: 26327627
[TBL] [Abstract][Full Text] [Related]
15. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
[TBL] [Abstract][Full Text] [Related]
16. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
17. Co-Stabilization of Amorphous Pharmaceuticals-The Case of Nifedipine and Nimodipine.
Knapik-Kowalczuk J; Tu W; Chmiel K; Rams-Baron M; Paluch M
Mol Pharm; 2018 Jun; 15(6):2455-2465. PubMed ID: 29738666
[TBL] [Abstract][Full Text] [Related]
18. Phase transformations undergone by Triton X-100 probed by differential scanning calorimetry and dielectric relaxation spectroscopy.
Merino EG; Rodrigues C; Viciosa MT; Melo C; Sotomayor J; Dionísio M; Correia NT
J Phys Chem B; 2011 Nov; 115(43):12336-47. PubMed ID: 21928821
[TBL] [Abstract][Full Text] [Related]
19. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies.
Seefeldt K; Miller J; Alvarez-Núñez F; Rodríguez-Hornedo N
J Pharm Sci; 2007 May; 96(5):1147-58. PubMed ID: 17455346
[TBL] [Abstract][Full Text] [Related]
20. Impact of surfactants on the crystal growth of amorphous celecoxib.
Mosquera-Giraldo LI; Trasi NS; Taylor LS
Int J Pharm; 2014 Jan; 461(1-2):251-7. PubMed ID: 24333451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
